What is Ironwood Pharmaceuticals, Inc.'s Shariah compliance score?

Ironwood Pharmaceuticals, Inc. (IRWD) has a Shariah compliance score of 61/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Ironwood Pharmaceuticals, Inc. pass AAOIFI screening?

Ironwood Pharmaceuticals, Inc. (IRWD) partially passes with caution AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (IRWD: 27.3%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Ironwood Pharmaceuticals, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Ironwood Pharmaceuticals, Inc. (IRWD) using the latest financial data.

Where can I screen Ironwood Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Ironwood Pharmaceuticals, Inc. (IRWD) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about IRWD's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

IRWD: Is Ironwood Pharmaceuticals, Inc. Halal?

Ironwood Pharmaceuticals, Inc.

NASDAQHealthcareUS

$4.31

-1.15%

Market Cap: 709.5M

Compliance Status

Doubtful

Screened on Sep 2, 2026 · AAOIFI Standard 21

Acceptable

61Score

Is Ironwood Pharmaceuticals, Inc. (IRWD) halal? Doubtful. Based on AAOIFI screening, Ironwood Pharmaceuticals, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 61/100 (Grade: B).

Quote this verdict

HalalScreener rates Ironwood Pharmaceuticals, Inc. (IRWD) Doubtful, 61/100, grade B under AAOIFI Standard 21, screened Sep 2, 2026. Source: https://halalscreener.app/en/stock/IRWD

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Close to the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

27.3% of 30.0% limit

What this means for you

You may own IRWD, with caution

Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.

Purification amount is Pro

We have screened IRWD's prohibited income, but the exact share you would need to purify is part of Pro.

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic

Why This Stock Is Doubtful

Debt is 27.3% of market cap, only 2.7 points below the 30% AAOIFI limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 2, 2026

Compliance History

Doubtfulnow
since Aug 2026
Not Halal
until the change above
Doubtful
until the change above
Not Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track IRWD and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Ironwood Pharmaceuticals, Inc. (IRWD) halal to invest in?

Ironwood Pharmaceuticals, Inc. (IRWD) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.

Why did Ironwood Pharmaceuticals, Inc. get a B compliance rating?

Ironwood Pharmaceuticals, Inc. (IRWD) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 27.3% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Ironwood Pharmaceuticals, Inc.'s Shariah verdict?

Ironwood Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Ironwood Pharmaceuticals, Inc. re-screened for Shariah compliance?

Ironwood Pharmaceuticals, Inc. (IRWD) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 2, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.